PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
30018229-1	2018	BACKGROUND: The MEK (mitogen-activated protein kinase)-inhibitor selumetinib led to increased radioiodine uptake and retention in a subgroup of patients suffering from radioiodine refractory differentiated thyroid cancer (RR-DTC).	Iodine-131	94-105	mitogen-activated protein kinase kinase 7	Homo sapiens	16-19	
30337961-0	2018	Synergistic inhibition of MEK/ERK and BRAF V600E with PD98059 and PLX4032 induces sodium/iodide symporter (NIS) expression and radioiodine uptake in BRAF mutated papillary thyroid cancer cells.	Iodine-131	127-138	mitogen-activated protein kinase kinase 7	Homo sapiens	26-29	
30018229-1	2018	BACKGROUND: The MEK (mitogen-activated protein kinase)-inhibitor selumetinib led to increased radioiodine uptake and retention in a subgroup of patients suffering from radioiodine refractory differentiated thyroid cancer (RR-DTC).	Iodine-131	94-105	mitogen-activated protein kinase kinase 7	Homo sapiens	21-53	
30018229-1	2018	BACKGROUND: The MEK (mitogen-activated protein kinase)-inhibitor selumetinib led to increased radioiodine uptake and retention in a subgroup of patients suffering from radioiodine refractory differentiated thyroid cancer (RR-DTC).	Iodine-131	168-179	mitogen-activated protein kinase kinase 7	Homo sapiens	16-19	
30018229-1	2018	BACKGROUND: The MEK (mitogen-activated protein kinase)-inhibitor selumetinib led to increased radioiodine uptake and retention in a subgroup of patients suffering from radioiodine refractory differentiated thyroid cancer (RR-DTC).	Iodine-131	168-179	mitogen-activated protein kinase kinase 7	Homo sapiens	21-53	
28291381-3	2017	The SELIMETRY trial (EudraCT No 2015-002269-47) aims to investigate the role of the MEK inhibitor Selumetinib in resensitizing advanced iodine refractory differentiated thyroid cancer to radioiodine therapy.	Iodine-131	187-198	mitogen-activated protein kinase kinase 7	Homo sapiens	84-87	
28423638-1	2017	Redifferentiation therapy with BRAF/MEK inhibitors to facilitate treatment with radioiodine represents a good choice for radioiodine-refractory differentiated thyroid carcinoma, but recent initial clinical outcomes were modest.	Iodine-131	80-91	mitogen-activated protein kinase kinase 7	Homo sapiens	36-39	
28423638-1	2017	Redifferentiation therapy with BRAF/MEK inhibitors to facilitate treatment with radioiodine represents a good choice for radioiodine-refractory differentiated thyroid carcinoma, but recent initial clinical outcomes were modest.	Iodine-131	121-132	mitogen-activated protein kinase kinase 7	Homo sapiens	36-39	
26338896-11	2015	Both the increased radioiodine uptake and ERK1/2 activation of ATC cells were completely inhibited by the specific MEK inhibitor.	Iodine-131	19-30	mitogen-activated protein kinase kinase 7	Homo sapiens	115-118	
17317846-10	2007	The results provide clinical implications that therapeutic targeting at the BRAF/MEK/MAP kinase pathway may be a good approach in restoring thyroid gene expression for effective radioiodine therapy for BRAF mutation-harboring PTC.	Iodine-131	178-189	mitogen-activated protein kinase kinase 7	Homo sapiens	81-84